Biomarkers and surrogate endpoints in renal transplantation: present status and considerations for clinical trial design. - Wikidata - wikimedia - TriplyDB

Biomarkers and surrogate endpoints in renal transplantation: present status and considerations for clinical trial design.

Biomarkers and surrogate endpoints in renal transplantation: present status and considerations for clinical trial design.

http://www.wikidata.org/entity/Q35691910

about

Tacrolimus versus cyclosporin as primary immunosuppression for kidney transplant recipients Safety and Efficacy Endpoints for Mesenchymal Stromal Cell Therapy in Renal Transplant Recipients Reconsidering the detection of tolerance to individualize immunosuppression minimization and to improve long-term kidney graft outcomes Tacrolimus versus ciclosporin as primary immunosuppression for kidney transplant recipients: meta-analysis and meta-regression of randomised trial data Biomarkers for early and late stage chronic allograft nephropathy by proteogenomic profiling of peripheral blood.Probabilistic (Bayesian) modeling of gene expression in transplant glomerulopathy Low-density array PCR analysis of reperfusion biopsies: an adjunct to histological analysis.The Biomarker-Surrogacy Evaluation Schema: a review of the biomarker-surrogate literature and a proposal for a criterion-based, quantitative, multidimensional hierarchical levels of evidence schema for evaluating the status of biomarkers as surrogat Standardized Outcomes in Nephrology-Transplantation: A Global Initiative to Develop a Core Outcome Set for Trials in Kidney Transplantation.High urinary excretion of kidney injury molecule-1 is an independent predictor of graft loss in renal transplant recipients.Biomarkers of over-immunosuppression.Kidney function endpoints in kidney transplant trials: a struggle for power.STANDARDIZED OUTCOMES IN NEPHROLOGY-PERITONEAL DIALYSIS (SONG-PD): STUDY PROTOCOL FOR ESTABLISHING A CORE OUTCOME SET IN PD.Toward Establishing Core Outcome Domains For Trials in Kidney Transplantation: Report of the Standardized Outcomes in Nephrology-Kidney Transplantation Consensus Workshops.Biomarkers in renal transplantation.A literature-based approach to evaluate the predictive capacity of a marker using time-dependent summary receiver operating characteristics.Qualification of biomarkers for drug development in organ transplantation.The predictive value of renal vascular resistance for late renal allograft loss.Erythrocyte glutathione transferase in kidney transplantation: a probe for kidney detoxification efficiency.

P2860

Q24245456-98E48621-5F43-4062-BAB1-626321F1289E Q26799916-A96D7E11-791B-4F6D-9E3C-1963EA4D94AB Q28080994-D7219C52-30D5-46AE-8FC9-0B8E57BA0210 Q31004418-F1CDD7D6-B420-48E6-A8E1-E84F38979BCC Q33480997-F96EA942-63DB-4C7C-9795-4E5EBA8816C8 Q34084853-6FF13CEB-2378-4A11-A258-2D04AAAA787C Q35025490-3F70EAC8-0A9F-416B-BF58-DC087806A2B5 Q36966415-FED3AEF7-D4E9-4925-BB71-920FF886ED50 Q37097834-50567C07-EFA8-4840-85B4-EEC4E547305E Q37349333-0BAAF352-EABF-4786-997B-5910304E12F3 Q37895908-DCACA087-FAB3-4A9F-B848-AB27A94D5276 Q39201859-2091EA16-78D8-4455-8DF1-BDE4BDC1C2CD Q39210349-A04A1CCA-061F-4AA4-B3D0-511CA513FC2E Q40122537-51AA400C-3556-4FD0-B1D2-416BEFEA30AB Q43061612-AE2633D2-67FE-4C17-9F2B-133635963507 Q45141248-72328BD0-0D9E-43ED-87C0-00FB16AD9FB4 Q45940767-A1279592-F3B2-4667-B27E-51F177D99999 Q46903632-8A1123AC-25E3-47A0-A266-1BFE4FFBFF54 Q49830036-0CC35A5A-68F6-4F2E-9627-5943D3B0B546

P2860

Biomarkers and surrogate endpoints in renal transplantation: present status and considerations for clinical trial design.

http://www.wikidata.org/entity/Q35691910

description

2004 nî lūn-bûn

@nan

2004年の論文

@ja

2004年論文

@yue

2004年論文

@zh-hant

2004年論文

@zh-hk

2004年論文

@zh-mo

2004年論文

@zh-tw

2004年论文

@wuu

2004年论文

@zh

2004年论文

@zh-cn

name

Biomarkers and surrogate endpo ...... ons for clinical trial design.

@ast

Biomarkers and surrogate endpo ...... ons for clinical trial design.

@en

type

label

Biomarkers and surrogate endpo ...... ons for clinical trial design.

@ast

Biomarkers and surrogate endpo ...... ons for clinical trial design.

@en

prefLabel

Biomarkers and surrogate endpo ...... ons for clinical trial design.

@ast

Biomarkers and surrogate endpo ...... ons for clinical trial design.

@en

P1433

Q35691910-7B5EC7F3-6E1B-4DEF-BB34-4FD6420891DD

P1476

Q35691910-9BDB32F2-501D-4137-91FD-BFFC2C522FD2

P2093

Q35691910-06C1BF32-AC07-4758-B565-4B3EEFFD6FC1

Q35691910-711146C8-F3CF-4810-B94C-EA9314FDA757

Q35691910-A8B8022D-3096-4660-8309-DEBA19B19CE9

Q35691910-BEA0D4C7-0391-41FA-8969-672FD1D33389

Q35691910-CD30262B-5329-425A-BAD4-459A7153EC0B

P2860

Q35691910-14B5FF07-A505-4B5D-8F2F-7379D781BAB6

Q35691910-21FD09D9-48D5-4F86-B209-EA3E84708E6A

Q35691910-4A6993CC-71D3-4971-8E70-C06AE0C5405C

Q35691910-4D9C840B-5F1C-451D-9277-4DA8164225B4

Q35691910-4FDCD272-FE92-4976-860E-7664C217D1DC

Q35691910-8E4C17DC-A2A3-473C-9529-D02501CE119D

Q35691910-8F82C14F-5B9E-412D-8EC2-EE776A2FEDBB

Q35691910-95EB974E-5874-4BBC-AF74-F5D0AED591C7

Q35691910-9BC03D18-D833-4341-8046-33B1465E23DB

Q35691910-AE76DF13-E922-439D-ADF3-6F2A7029EE65

P304

Q35691910-BB33DA2C-8AE9-42DA-B0E9-4950FFE48028

P31

Q35691910-B270DBAD-8C51-4A98-889A-551DBA008524

P356

Q35691910-0665671A-0DC2-4603-8817-D4B304486417

P407

Q35691910-F4AA6970-30DE-43F5-9CFF-0C464F75A535

P433

Q35691910-DFD10633-D41F-46AE-906C-585C753BEA3C

P478

Q35691910-8BB8B66F-1981-4504-8870-355912D34159

P577

Q35691910-60943CF1-AB00-4C48-998F-F3E19EBC9DA9

P5875

Q35691910-36ECFA28-7B8C-46E0-8F05-D4AEFDEDF300

P698

Q35691910-412A8283-6FB6-4638-BB70-C8CE40818E1A

P921

Q35691910-7764D6ED-FD29-49FB-A3CC-9F336E6E2D44

P356

J.1600-6143.2004.00386.X

P1433

American Journal of Transplantation

P1476

Biomarkers and surrogate endpo ...... ons for clinical trial design.

@en

P2093

Amy S Rosenberg

http://www.w3.org/2001/XMLSchema#string

Ezio Bonvini

http://www.w3.org/2001/XMLSchema#string

Marc W Cavaillé-Coll

http://www.w3.org/2001/XMLSchema#string

Peter A Lachenbruch

http://www.w3.org/2001/XMLSchema#string

Robert B Colvin

http://www.w3.org/2001/XMLSchema#string

P2860

Increased expression of cytotoxic effector molecules: different interpretations for steroid-based and steroid-free immunosuppression

Glomerular filtration rate as a putative 'surrogate end-point' for renal transplant clinical trials in children.

Quantitative detection of immune activation transcripts as a diagnostic tool in kidney transplantation

Gene expression analysis in human renal allograft biopsy samples using high-density oligoarray technology.

Effect of histological damage on long-term kidney transplant outcome.

Noninvasive diagnosis of renal-allograft rejection by measurement of messenger RNA for perforin and granzyme B in urine.

High transforming growth factor-beta and extracellular matrix mRNA response in renal allografts during early acute rejection is associated with absence of chronic rejection.

Quantitative detection of T-cell activation markers by real-time PCR in renal transplant rejection and correlation with histopathologic evaluation.

Antibody-mediated rejection criteria - an addition to the Banff 97 classification of renal allograft rejection.

Early prognosis of the development of renal chronic allograft rejection by gene expression profiling of human protocol biopsies.

P304

451-457

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/J.1600-6143.2004.00386.X

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

4

http://www.w3.org/2001/XMLSchema#string

P577

2004-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

5265861

http://www.w3.org/2001/XMLSchema#string

P698

15023136

http://www.w3.org/2001/XMLSchema#string

P921